Make money? Yes, Icahn
This article was originally published in Scrip
So we know that activist shareholder Carl Icahn, after waging two proxy battles and threatening another to change the leadership and strategy at Forest Laboratories, will trouser a cool $600 million plus profit if Actavis succeeds in its $25bn bid for the US specialty pharma company (scripintelligence.com 19 February 2014 & 18 February 2014). And he is not the only winner as any other shareholders who bought Forest stock mid November 2009, at the same time as Icahn Associates, will have realized a 209% return.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.